The effect of anthracyclines on myocardial function in 50 long-term survivors of childhood cancer

Cardiovascular Journal of South Africa

Volumn 89, Issue 1, 1998, Pages

  Hesseling, P B ^a   Kalis, N N ^a   Wessels, G ^a   Van Der Merwe, P L ^a  

^a STELLENBOSCH UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; FEMALE; HEART FAILURE; HEART FUNCTION; HUMAN; MALE; ST SEGMENT; T WAVE;

EID: 0032951360     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rhoden W, Haselton P, Brooks N. Anthracyclines and the heart. Br Heart J 1993; 70: 499-502.
2. Hitchcock-Bryan S, Gelber RD, Cassady JR, Sallan SE. The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 1986; 14: 211-215.
3. Waagstein F, Fu LX, Hjalmarson A. A new insight into adriamycin-induced cardiotoxicity. Int J Cardial 1990; 29: 15-20.
4. Von Hoff DD, Rosencweig M, Layard M, Slavic M, Muggia FM. Daunomycin-induced cardiotoxicity in children and adults: a review of 110 cases. Am J Med 1977; 62: 200-208.
5. Steinberg JS, Cohen AJ, Wasserman AG, Cohen P, ROSS AM. Acute arrhythmogenicity of doxorubicin administration. Cancer 1987; 60: 1213-1218.
6. Fazio ACS, Basso CD, Bazzicalupo L, Picardi G, Sacca L. Subclinical cardiotoxicity by doxorubicin: a pulsed Doppler echocardiographic study. Eur Heart J 1991; 12: 1000-1005.
7. Marchandise B, Schroeder E. Bosley A, et al. Early detection of doxorubicin cardiotoxicity: interest of Doppler echocardiographic analysis of left ventricular filling dynamics. Am Heart J 1989; 118: 92-98.
8. Bu'Lock FA, Molt MG, Martin RP. Doppler echocardiographic detection of anthracycline induced changes in diastolic ventricular function in children (Abstract). Br Heart J 1990; 64: 85.
9. Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 1991; 324: 808-815.
10. Truesdell S, Schwartz Cl, Clark E, Constine LS. Cardiovascular effects of cancer therapy. In: Schwanz CL, Hobbie WL, Constine LS, Ruccione KS, eds. Survivors of Childhood Cancer. St Louis: Mosby, 1994: 159-174.
11. Riehm H, Henze G, Komhuber B, et al. Results and significance of six randomised trials in four consecutive ALL-BFM studies. Haematology and Blood Transfusion 1990; 33: 439-450.
12. Creutzig U, Ritter J, Riehm H, et al. The childhood AML studies BFM-78 and BFM-83: Treatment results and risk factors analysis. In: Buchner T, Schellong G, Hiddeman W, eds. Acute Leukaemias, Haematology and Blood Transfusion. Berlin: Springer-Verlag, 1987.
13. Bonadonna G, Zucali R, Monfardini S, Delena M, Vslenghi C. Combination chemotherapy in Hodgkin's disease with adriamycin, bleomycin, vinblastine and imidazole carboxamide versus MOPP. Cancer 1975; 36: 252-259.
14. Martin J, Radford M. Current practice in Hodgkin's disease. The United Kingdom Children's Cancer Study Group. In: Kamps WA, Humphrey GB, Poppema S, eds. Hodgkin's Disease in Children: Controversies and Current Practice. Boston: Kluwer, 1989: 263-275.
15. Anderson JR, Wilson JF, Jenkin RDT. Childhood non Hodgkin's lymphoma: the results of a randomised therapeutic trial comparing a 4-drug regime (LSA2-L2). N Engl J Med 1983; 308: 559-565.
16. D'Angio GJ, Breslow N, Beckwith JB, et al. Treatment of Wilms' tumour: results of the Third National Wilms' Tumour Study. Cancer 1989; 64: 349.
17. Habrand JL, Carli M. Results of SIOP nephroblastoma trial 6 and 9. Paper presented at the 21st meeting of SIOP (International Society of Paediatric Oncology), Prague, 18-22 Sep 1989.
18. Green AA, Hayes FA, Hustu HO. Sequential cyclophosphamide and doxorubicin for induction of complete remission in children with disseminated neuroblastoma. Cancer 1981; 48: 2310-2317.
19. Hammer LD, Kraemer HC, Wilson DM, Ritter PL, Dornbusch SM. Standardized percentile curves of body-mass index for children and adolescents. Am J Dis Child 1991; 145: 259-263.
20. Von Hoff DD, Rozencweig M, Piccart M. The cardiotoxicity of anti-cancer agents. Semin Oncol 1982; 9: 23-33.
21. Gottlieb JA, Lefrak EA, O'Brein RM, Burgess A. Fatal adriamycin cardiomyopathy (CMY): Prevention by dose limitation (Abstract). Proc Am Assoc Cancer Res 1973; 14: 88.
22. LeFrak EA, Pitha J, Rosenheim S, Gottleib J. A clinicopathologic analysis of adriamycin toxicity. Cancer 1973; 32: 302-314.
23. Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 1981; 102: 709-718.
24. Yeung ST, Young C, Spink J, Galbraith A, Smith PJ. Functional myocardial impairment in children treated with anthracyclines for cancer. Lancet 1991; 337: 816-818.
25. Steinherz LJ, Steinherz PG, Tan CTC, Heller G, Murphy L. Cardiotoxicity 4 to 20 years after completing anthracycline therapy. JAMA 1991; 266: 1672-1677.
26. Jakacki RI, Larsen RL, Barber G, Heyman S, Fridman M, Silber JH. Comparison of cardiac function tests after anthracycline therapy in childhood. Implications for screening. Cancer 1993; 73: 2739-2745.
27. De Wolf D, Suys B, Mauras R, et al. Dobutamine stress echocardiography in the evaluation of late anthracycline cardiotoxicity in childhood cancer survivors. Pediatr Res 1996; 39: 504-512.
28. Gill PS, Espina BM, Muggia F, et al. Phase I/II clinical and pharmacokinetic evaluation of liposomal daunorubicin. J Clin Oncol 1995; 13: 996-1003.
29. Forssen EA, Malé-Brune R, Adle-Moore JP, et al. Fluorescence imaging studies for the disposition of daunorubicin liposomes (Dauno-Xome) within tumor tissue. Cancer Res 1996; 56: 2066-2075.
30. Wexler LH, Adrich MP, Venzon D, et al. Randomised trial of the cardiac-protective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol 1996; 14: 362-367.